Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Idiopathic psychotic disorders, such as schizophrenia and schizoaffective disorder, often require adjunctive treatments for improved outcomes.
• Histamine-2 (H2) receptor antagonists are primarily used for acid reflux but may have unexplored neurological applications.
• Treatment resistance and frequent hospitalizations are significant challenges in managing schizophrenia.

Purpose of the Study:

• To investigate the efficacy of famotidine as an adjunct to conventional antipsychotic therapy in patients with idiopathic psychotic disorders.
• To assess the impact of famotidine on overall psychiatric symptoms and negative symptoms in schizophrenia patients.

Main Methods:

• An open-label study involving 10 treatment-refractory patients with schizophrenia or schizoaffective disorder.
• Famotidine (20 mg twice daily) was added to existing antipsychotic regimens for 3 weeks.
• Symptom severity was assessed using the Brief Psychiatric Rating Scale (BPRS) and the Schedule for the Assessment of Negative Symptoms (SANS).

Main Results:

• Significant reductions in total BPRS and Clinical Global Impression scores were observed during famotidine treatment.
• Improvements were primarily noted in specific symptom subscales of the BPRS, not negative symptoms (SANS).
• The magnitude of symptom improvement was generally small, despite statistical significance.

Conclusions:

• Famotidine may offer a potential adjunctive benefit for specific symptoms in some schizophrenia patients.
• Larger, double-blind, placebo-controlled trials with higher famotidine doses are warranted.
• Exploring other H2 receptor antagonists with enhanced blood-brain barrier penetration could be beneficial.